CoChat

A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach

Open access
Rochester, Lynn, Mazzà, Claudia, Mueller, Arne, Caulfield, Brian, McCarthy, Marie, Becker, Clemens, Miller, Ram, Piraino, Paolo, Viceconti, Marco, Dartee, Wilhelmus P., Garcia-Aymerich, Judith, Aydemir, Aida A., Vereijken, Beatrix, Arnera, Valdo, Ammour, Nadir, Jackson, Michael, Hache, Tilo, Roubenoff, Ronenn, on behalf of the Mobilise-D Consortium · 2020 · Digital Biomarkers
Cited by 140

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000512513

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 140

Metadata

Authors
Rochester, L., Mazzà, C., Mueller, A., Caulfield, B., McCarthy, M., Becker, C., Miller, R., Piraino, P., Viceconti, M., Dartee, W. P., Garcia-Aymerich, J., Aydemir, A. A., Vereijken, B., Arnera, V., Ammour, N., Jackson, M., Hache, T., Roubenoff, R., & on behalf of the Mobilise-D Consortium
Venue
Digital Biomarkers
Publisher
S. Karger AG
Published
2020-11-26
Volume
4
Issue
Suppl. 1
Pages
13-27
ISSN
2504-110X (ISSN-L)
OpenAlex
W3107368598
Cited by
140
References
12
FWCI
15.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach. https://app.cochat.ai/papers/10.1159/000512513
The paper
Rochester, L., Mazzà, C., Mueller, A., Caulfield, B., McCarthy, M., Becker, C., Miller, R., Piraino, P., Viceconti, M., Dartee, W. P., Garcia-Aymerich, J., Aydemir, A. A., Vereijken, B., Arnera, V., Ammour, N., Jackson, M., Hache, T., Roubenoff, R., & on behalf of the Mobilise-D Consortium. (2020). A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach. Digital Biomarkers. https://doi.org/10.1159/000512513

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.